Welcome to the latest of our Eberhard F. Mammen Award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2022 represents in excess of 10 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:
-
● Most popular article awards: Awarded to the authors of the most popular articles published in STH. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, errata, letters to the editor, editorials, commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Open Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “free to download” status for these articles thereafter.
-
● Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the current coronavirus disease 2019 (COVID-19) pandemic, many international congresses have become virtual meetings, and accordingly, virtual meeting presentations can also be considered for the award.
Fig. 1 Eberhard F. Mammen (1930–2008).
Table 1
Previous editorials related to Eberhard F. Mammen Award announcements
|
1. Favaloro EJ. Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008;34:693–696
2. Favaloro EJ. A Tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008;34:703–708
3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009;35:1–2
4. Favaloro EJ. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. Semin Thromb Hemost 2009;35:587–590
5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. Semin Thromb Hemost 2010;36:469–470
6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009. Semin Thromb Hemost 2010;36(7):685–692
7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011;37(5):431–439
8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012;38:425–432
9. Favaloro EJ. 2013 Eberhard F. Mammen award announcements. Semin Thromb Hemost 39:567–574
10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: Part I - most popular articles. Semin Thromb Hemost 2014;40(4):407–412
11. Favaloro EJ. 2014 Eberhard F. Mammen Award Announcements: Part II - Young Investigator Awards. Semin Thromb Hemost 2014;40(7):718–723
12. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2015;41(7):673–679
13. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2015;41(8):809–815
14. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2016;42(4):325–330
15. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2017;43(3):235–241
16. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2017;43(4):357–363
17. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2018;44(2):81–88
18. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2018;44(3):185–192
19. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2019;45(2):123–129
20. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2019;45(3):215–224
21. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2020;46(2):105–113
22. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2020;46(4):383–392
23. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2021;47(3):229–237
24. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2021;47(5):467–476
25. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2022;48(3):265–273
|
Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print ([Table 1]). This includes the recent announcement of the 2021 Young Investigator Awards.[1]
It is therefore with great pleasure that we would like to announce the latest winners of the 2022 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2020 to 2021 inclusive.
2022 “Most Popular” Article Awards
As mentioned, the Most Popular awards are given to the authors of the most popular articles published in STH as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year period. Thus, the 2022 “Most Popular” awards are granted to the most popular papers in the years 2020 and 2021 inclusive. Previous Eberhard F. Mammen award winning articles are listed in [Table 2]. These articles are currently freely available online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and no longer qualify for future awards, although many will continue to appear in the most popular download statistics provided by the publisher. Indeed, as expected, many of the previous award-winning articles appeared in the top 100 list (2020–2021 inclusive), with most also ranking highly, and thus still proving popular with our readership.
Table 2
Previous most popular award-winning papers
|
Year
|
Awarded for
|
Position in 2022 top 100 list
|
|
2009
|
Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31(4):381–392
|
11
|
|
2009
|
Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32(8):803–809
|
NL
|
|
2010
|
Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34(1):39–57
|
NL
|
|
2010
|
Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008;34(1):86–96
|
NL
|
|
2010
|
Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34(1):58–73
|
NL
|
|
2011
|
Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009;35(5):515–524
|
NL
|
|
2011
|
Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost 2009;35(4):400–406
|
30
|
|
2012
|
Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” Semin Thromb Hemost 2010;36(1):59–70
|
22
|
|
2012
|
Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906
|
67
|
|
2013
|
Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011;37(3):280–297
|
54
|
|
2013
|
Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011;37(3):267–274
|
32
|
|
2014
|
Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012;38(1):23–30
|
NL
|
|
2014
|
Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012;38(1):47–54
|
70
|
|
2014
|
Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011;37(7):802–809
|
34
|
|
2015
|
Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost 2013;39(4):452–458
|
NL
|
|
2015
|
George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013;39(2):153–160
|
66
|
|
2015[a]
|
Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013;39(2):147–152
|
NL
|
|
2015[a]
|
Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013;39(2):117–126
|
NL
|
|
2016
|
de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39(6):585–595
|
20
|
|
2016
|
Sethi S, Fervenza FC. Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS). Semin Thromb Hemost 2014;40(4):416–421
|
74
|
|
2016[a]
|
Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012;38(7):673–682
|
53
|
|
2016[a]
|
Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014;40(1):60–65
|
29
|
|
2017
|
Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost 2015;41(1):68–74
|
23
|
|
2017
|
Levi M, Poll TV. Coagulation in patients with severe sepsis. Semin Thromb Hemost 2015;41(1):9–15
|
65
|
|
2017[a]
|
Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014;40(2):163–171
|
25
|
|
2017[a]
|
Warkentin TE. Heparin-Induced Thrombocytopenia in critically Ill patients. Semin Thromb Hemost 2015;41(1):49–60
|
86
|
|
2017[b]
|
Favaloro EJ, Lippi G. Laboratory Testing in the era of direct or non-vitamin k antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 2015;41(2):208–227
|
NL
|
|
2018
|
Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016;42(3):191–204
|
2
|
|
2018
|
Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. Semin Thromb Hemost 2015;41(5):527–537
|
48
|
|
2018[a]
|
Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 2015;41(4):395–404
|
NL
|
|
2018[a]
|
Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014;40(1):106–114
|
84
|
|
2019
|
Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. Semin Thromb Hemost 2018;44(4):353–363
|
37
|
|
2019
|
Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and Factor IX Replacement Therapies. Semin Thromb Hemost 2017;43(3):331–337
|
58
|
|
2019[a]
|
Kell DB, Pretorius E. To What Extent Are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin? Semin Thromb Hemost 2018;44(3):224–238
|
40
|
|
2019[a]
|
Chighizola CB, Raimondo MG, Meroni PL. Management of thrombotic antiphospholipid syndrome. Semin Thromb Hemost 2018;44(5):419–426
|
97
|
|
2020
|
Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019;45(7):661–673
|
1
|
|
2020
|
Russo V, Attena E, Mazzone C, Esposito F, Parisi V, Bancone C, Rago A, Nigro G, Sangiuolo R, D' Onofrio A. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018;44(4):364–369
|
93
|
|
2020[a]
|
Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018;44(8):780–786
|
35
|
|
2020[a]
|
Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017;43(6):562–571
|
26
|
|
2021
|
Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost 2020 Feb;46(1):89–95
|
8
|
|
2021
|
Thomas J, Kostousov V, Teruya J. Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation. Semin Thromb Hemost 201844(1):20–29
|
24
|
|
2021[a]
|
Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret V. International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting. Semin Thromb Hemost 2020;46(4):398–409
|
3
|
|
2021[a]
|
Gosselin RC, Marlar RA. Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results. Semin Thromb Hemost 2019;45(5):433–448
|
15
|
Abbreviation: NL, not listed in top 100 listing.
a New “open access” category created in 2015.
b This paper qualified as a “Most Popular” award winner based on objective publisher-provided download data; however, as this paper was written by the journal Editor in Chief, there was an obvious conflict of interest, and the award was officially declined. This paper is listed here merely as a statement of record.
There is also an increasingly recognized trend to publish articles under an open-access model, and these therefore have an “inequitable advantage” over other “non-open access” articles in terms of potential for downloads or perceived popularity due to their open accessibility. Accordingly, the publisher of STH established separate categories of the Most Popular award for “open-access” papers and an alternate “General Category” (non-open access). Consequently, the most popular papers from each category are now listed in separate tables. [Table 3] lists the top 25 downloaded “free to download” articles from STH (2020 and 2021 inclusive), as eligible for the “Open Access” award.[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[Table 4] lists the top 25 downloaded non-open access articles from STH (2020 and 2021 inclusive), as otherwise eligible for the “General category” award.[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
Table 3
Most popular papers—“Open Access” category[a]
|
Rank
|
Publication
|
|
1
|
Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020;46(7):763–771
|
|
2
|
Allaoui A, Khawaja AA, Badad O, Naciri M, Lordkipanidzé M, Guessous F, Zaid Y. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021;47(4):419–426
|
|
3
|
Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost 2020 Apr;46(3):275–288.
|
|
4
|
Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost 2020 ;46(3):302–319
|
|
5
|
Zadow EK, Wundersitz DWT, Hughes DL, Adams MJ, Kingsley MIC, Blacklock HA, Wu SSX, Benson AC, Dutheil F, Gordon BA. Coronavirus (COVID-19), coagulation, and exercise: interactions that may influence health outcomes. Semin Thromb Hemost 2020;46(7):807–814
|
|
6
|
Christensen B, Favaloro EJ, Lippi G, Van Cott EM. Hematology laboratory abnormalities in patients with coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 2020;46(7):845–849
|
|
7
|
Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost 2020;46(7):796–803
|
|
8
|
Fernández-Capitán C, Barba R, Díaz-Pedroche MDC, Sigüenza P, Demelo-Rodriguez P, Siniscalchi C, Pedrajas JM, Farfán-Sedano AI, Olivera PE, Gómez-Cuervo C, Llamas P, Villares P, Sanchez O, López-Reyes R, Catella J, Bikdeli B, Weinberg I, Tafur AJ, Jiménez D, Monreal M. presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. Semin Thromb Hemost 2021;47(4):351–361
|
|
9
|
Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019;45(1):86–93
|
|
10
|
Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment of the new roche cobas t 711 fully automated coagulation analyzer. Semin Thromb Hemost 2019;45(3):308–314
|
|
11
|
Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: A Meta-Analysis. Semin Thromb Hemost 2021;47(4):392–399
|
|
12
|
Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021;47(4):372–391
|
|
13
|
Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting Anti-IIa and Anti-Xa Direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost 2019;45(3):275–284
|
|
14
|
Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous Thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021;47(4):362–371
|
|
15
|
Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009;35(2):189–203.
|
|
16
|
Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008 Nov;34(8):709–733
|
|
17
|
Orsi FA, Cannegieter SC, Lijfering WM. Statin Therapy to revert hypercoagulability and prevent venous thromboembolism: a narrative review. Semin Thromb Hemost 2019;45(8):825–833
|
|
18
|
van der Vorm LN, Huskens D, Kicken CH, Remijn JA, Roest M, de Laat B, Miszta A. Effects of Repeated Bouts of Exercise on the Hemostatic System. Semin Thromb Hemost 2018 Nov;44(8):710–722.
|
|
19
|
Stillson JE, Bunch CM, Gillespie L, Khan R, Wierman M, Pulvirenti J, Phyu H, Anderson S, Al-Fadhl M, Thomas AV, Kwaan HC, Moore E, Moore H, Walsh MM. Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage. Semin Thromb Hemost 2021 Jun;47(4):442–446.
|
|
20
|
Demers M, Wagner DD. NETosis: A New Factor in Tumor Progression and Cancer-Associated Thrombosis. Semin Thromb Hemost 2014 Apr;40(3):277–83.
|
|
21
|
Bezuidenhout JA, Pretorius E. The Central Role of Acute Phase Proteins in Rheumatoid Arthritis: Involvement in Disease Autoimmunity, Inflammatory Responses, and the Heightened Risk of Cardiovascular Disease. Semin Thromb Hemost 2020 Jun;46(4):465–483.
|
|
22
|
Lippi G, Danese E, Favaloro EJ. Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview. Semin Thromb Hemost 2019 Mar;45(2):157–163.
|
|
23
|
Favaloro EJ, Henry BM, Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin Thromb Hemost 2021 Jun;47(4):400–418.
|
|
24
|
Favaloro EJ, Pasalic L, Curnow J. Type 2M and Type 2A von Willebrand Disease: Similar but Different. Semin Thromb Hemost 2016 Jul;42(5):483–97.
|
|
25
|
Leiderman K, Sindi SS, Monroe DM, Fogelson AL, Neeves KB. The Art and Science of Building a Computational Model to Understand Hemostasis. Semin Thromb Hemost 2021 Mar;47(2):129–138.
|
a 2020–2021 inclusive. Ranking is according to download data provided by journal publisher, and excludes nonqualifying material (e.g., prefaces, errata, letters to the editor, editorials, commentaries, and previous award-winning articles).
Table 4
Most popular papers—“General' category”[a]
|
Rank
|
Publication
|
|
(i) Articles published in the past 5 years
|
|
1
|
Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 2020;46(8):932–969
|
|
2
|
Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. fibrinogen supplementation and its indications. Semin Thromb Hemost 2020;46(1):38–49
|
|
3
|
Black JA, Pierce VS, Kerby JD, Holcomb JB. The evolution of blood transfusion in the trauma patient: whole blood has come full circle. Semin Thromb Hemost 2020;46(2):215–220
|
|
4
|
Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost 2019;45(4):321–325
|
|
5
|
Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost 2017;43(3):270–276
|
|
6
|
Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 2017;43(3):253–260
|
|
7
|
Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost 2020;46(8):865–871
|
|
8
|
Abeysiri S, Chau M, Richards T. Perioperative anemia management. semin thromb hemost 2020;46(1):8–16
|
|
9
|
Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost 2019 ;45(6):604–611
|
|
10
|
Levi M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost 2019;45(4):342–347
|
|
11
|
Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin Thromb Hemost 2017;43(4):386–396
|
|
12
|
Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 2019;45(1):22–35
|
|
13
|
Fang ZA, Navaei AH, Hensch L, Hui SR, Teruya J. Hemostatic management of extracorporeal circuits including cardiopulmonary bypass and extracorporeal membrane oxygenation. Semin Thromb Hemost 2020;46(1):62–72
|
|
14
|
Marongiu F, Mameli A, Grandone E, Barcellona D. Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism? Semin Thromb Hemost 2019;45(8):778–783
|
|
15
|
Babin JL, Traylor KL, Witt DM. Laboratory monitoring of low-molecular-weight heparin and fondaparinux. Semin Thromb Hemost 2017;43(3):261–269
|
|
16
|
Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary Embolism and atrial fibrillation: two sides of the same coin? a systematic review. Semin Thromb Hemost 2017;43(8):849–863
|
|
17
|
Mensah PK, Pavord S. Managing preoperative hemostasis in patients with inherited and acquired bleeding disorders. Semin Thromb Hemost 2020;46(1):17–25
|
|
18
|
Lippi G, Danese E, Favaloro EJ. Vascular disease and dementia: lipoprotein(a) as a neglected link. Semin Thromb Hemost 2019;45(5):544–547
|
|
19
|
Tabibian S, Shiravand Y, Shams M, Safa M, Gholami MS, Heydari F, Ahmadi A, Rashidpanah J, Dorgalaleh A. A comprehensive overview of coagulation factor v and congenital factor v deficiency. Semin Thromb Hemost 2019;45(5):523–543
|
|
20
|
Nikolakopoulos I, Spyropoulos AC. Heparin bridging therapy for patients on chronic oral anticoagulants in periprocedural settings. Semin Thromb Hemost 2020;46(1):26–31
|
|
(i) Articles published more than 5 years ago
|
|
1
|
Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012;38(8):865–883
|
|
2
|
Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004;30(5):579–589
|
|
3
|
Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014 Jul;40(5):571–576
|
|
4
|
Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23(4):349–356.
|
|
5
|
Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006 Apr;32 (Suppl 1):3–15
|
a 2020–2021 inclusive. Ranking is according to download data provided by journal publisher, and excludes nonqualifying material (e.g., prefaces, errata, letters to the editor, editorials, commentaries, and previous award-winning articles).
Therefore, the 2022 Eberhard F. Mammen award winners for most popular article (2020/2021 inclusive) are:
Open Access Category
-
Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin Thromb Hemost 2020 Oct;46(7):763–771.[2]
-
Allaoui A, Khawaja AA, Badad O, Naciri M, Lordkipanidzé M, Guessous F, Zaid Y. Platelet Function in Viral Immunity and SARS-CoV-2 Infection. Semin Thromb Hemost 2021 Jun;47(4):419–426.[3]
General Category
-
Abildgaard A, Madsen SA, Hvas AM. Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. Semin Thromb Hemost 2020 Nov;46(8):932–969.[27]
-
Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Fibrinogen Supplementation and Its Indications. Semin Thromb Hemost 2020 Feb;46(1):38–49.[28]
As always, I always get considerable satisfaction in announcing these awards. This year saw the topic of COVID-19 take prominence, not only worldwide, but also in this journal, including the most downloaded “free to download” papers.[2]
[3] Indeed, one of these papers was published in 2021,[3] and so is perhaps especially deserving, given its late publication of the 2-year 2020/2021 capture period. I actually predicted that COVID-19-related reviews would likely win the 2022 most popular awards in my previous (2021) editorial.[52] Indeed, quite a few other COVID-19-related papers also appeared in the top-100 download list, including in the top 25 “open access” category ([Table 3]). Thieme, the publisher of STH, is providing a large number of COVID-19-related papers free to download from their Web site (https://www.thieme.com/resources/1721-coronavirus), and STH material is no exception, with most COVID-19-related resources published by STH also being free to download. To date, we have published three issues of STH related to COVID-19,[53]
[54]
[55] and all have proven very popular with the readership. Indeed, STH published a series of “editorial” commentaries early in the COVID-19 pandemic ([Table 5]). These have also proved very popular with the readership, and were listed in the top 100 list; however, these do not qualify for the most popular awards.
Table 5
COVID-19-related commentaries—also very popular[a]
|
Publication
|
Position in 2022 top 100 list
|
|
Favaloro EJ, Lippi G. recommendations for minimal laboratory testing panels in patients with covid-19: potential for prognostic monitoring. Semin Thromb Hemost 2020;46(3):379–382
|
4
|
|
Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? Semin Thromb Hemost 2020;46(7):777–780
|
5
|
|
Schulman S. Coronavirus Disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost 2020;46(7):772–776
|
12
|
|
Larsen JB, Pasalic L, Hvas AM. Platelets in coronavirus disease 2019. Semin Thromb Hemost 2020;46(7):823–825
|
13
|
|
Kwaan HC. Coronavirus Disease 2019: the role of the fibrinolytic system from transmission to organ injury and sequelae. Semin Thromb Hemost 2020 ;46(7):841–844
|
14
|
|
de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. impaired breakdown of bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19 infection. Semin Thromb Hemost 2020;46(7):835–837
|
17
|
|
Levi M, Thachil J. Coronavirus Disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost 2020;46(7):781–784
|
21
|
|
Coppola A, Tagliaferri A, Rivolta GF, Quintavalle G, Franchini M. Confronting COVID-19: Issues in Hemophilia and congenital bleeding disorders. Semin Thromb Hemost 2020;46(7):819–822
|
27
|
|
Hashemi A, Madhavan MV, Bikdeli B. pharmacotherapy for prevention and management of thrombosis in COVID-19. Semin Thromb Hemost 2020;46(7):789–795
|
38
|
|
Horowitz NA, Brenner B. thrombosis and hemostasis issues in cancer patients with COVID-19. Semin Thromb Hemost 2020;46(7):785–788
|
45
|
|
Dorgalaleh A. Bleeding and Bleeding Risk in COVID-19. Semin Thromb Hemost 2020t;46(7):815–818
|
46
|
|
Thachil J, Lisman T. pulmonary megakaryocytes in coronavirus disease 2019 (COVID-19): roles in thrombi and fibrosis. Semin Thromb Hemost 2020 Oct;46(7):831–834
|
49
|
|
Amgalan A, Malinowski AK, Othman M. COVID-19 and sex-/gender-specific differences: understanding the discrimination. Semin Thromb Hemost 2021 ;47(4):341–347
|
50
|
|
Franchini M, Del Fante C, Klersy C, Glingani C, Percivalle E, Baldanti F, Perotti C. Challenges in the production of convalescent hyperimmune plasma in the age of COVID-19. Semin Thromb Hemost 2020;46(7):804–806
|
52
|
|
Parra-Izquierdo I, Aslan JE. Perspectives on platelet heterogeneity and host immune response in coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 2020;46(7):826–830
|
55
|
|
Harenberg J, Bauersachs R, Ageno W. Does chronic treatment with oral anticoagulants ameliorate the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in coronavirus disease 2019 (COVID-19)? Semin Thromb Hemost 2021;47(4):338–340
|
57
|
|
Nadir Y, Brenner B. Relevance of heparan sulfate and heparanase to severity of COVID-19 in the elderly. Semin Thromb Hemost 2021;47(4):348–350
|
80
|
a 2020–2021 inclusive. Ranking is according to download data provided by journal publisher. Most COVID-19-related material provided as free to download by Thieme. All material in this table is included in the material freely available on the publisher Web site (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077).
As always, the listing also identified some older yet still popular papers, especially those in the general category ([Table 4]), and thus indicating some topics of current interest that STH will likely revisit in forthcoming years. “Old” but popular topics include “aspirin”[50] and “thrombin”[51], and I would note that STH has published more recent papers on these topics.[23]
[56]
It is also always of interest to see what else captures the attention of the STH readership. Some topics and issues of STH, in particular, seem to catch a larger readership. In addition to COVID-19-related papers, this broadly included topics related to laboratory diagnostics[11]
[16]
[17]
[25]
[38]
[45] or anticoagulants[14]
[27]
[46] or monitoring of anticoagulant therapy,[31]
[32]
[41] and neutrophil extracellular traps[10]
[21] to name a few. We expect to provide more reading material on these topics in future issues of the journal.
Other than the COVID-19 issues, the other top-ranking issues of STH this round, from the aspect of having three or more papers appearing in the top 100 download list and published in the past 5 years were: “Editorial Compilation VII.” (2019)[57] and “Perioperative Thrombosis and Hemostasis.” (2020).[58] However, it is clear that the overwhelming popularity of the COVID-19 issues, with 32 papers listed in the top 100 downloaded list, basically took up the critical mass in the listing, and preventing other issues being more prominently listed on this occasion.
All authors of the award-winning articles were thrilled to hear that their papers had won an Eberhard F. Mammen Most Popular award, and provided their own personal responses to the news.
From Matteo Di Minno and Pasquale Ambrosino, speaking on behalf of all coauthors ([Fig. 2]), “We are greatly honored to have received one of the ‘2022 Eberhard F. Mammen Seminars in Thrombosis and Hemostasis Most Popular Awards.’ We are delighted and thrilled that our manuscript on a topic of great interest in this pandemic period has been widely read by the scientific community. A major concern in severe COVID-19 is represented by a concomitant pro-thrombotic state. Thus, the aim of our meta-analysis was to provide timely information on the cumulative prevalence of venous thromboembolism in this clinical setting. It was gratifying to observe that our findings, although published at an early stage of the pandemic, were later confirmed by subsequent studies. Therefore, we found that our work was truly necessary and that it has hopefully increased the focus on the need for adequate screening procedures and antithrombotic strategies in COVID-19 patients. We are extremely happy to have presented our findings in this prestigious journal.”
Fig. 2 From left: Alessandro Di Minno, Pasquale Ambrosino, Ilenia Calcaterra, Matteo Nicola Dario Di Minno.
From Dr. Younes Zaid ([Fig. 3]), speaking on behalf of all authors (some of whom also appear in [Fig. 3]), “It is a true privilege and great honor to be granted one of two Eberhard F. Mammen Seminars in Thrombosis and Hemostasis 2022 Most Popular Article Awards for the ‘Open Access Category,’ for our article entitled ‘Platelet Function in Viral Immunity and SARS-CoV-2 Infection.’ We were pleasantly surprised and really thrilled to hear that our paper reached a large readership; and this comforts our goal of enlightening the scientific community about platelet contribution to antiviral immunity and response during SARS-CoV-2 infection. Most importantly, we would like to thank the editors of STH for giving us the opportunity to publish our work in this prestigious journal. The award will be spent wisely to further fund our research related to COVID-19.”
Fig. 3 From left: Younes Zaid, Marie Lordkipanidzé, Fadila Guessous.
From Anne-Mette Hvas ([Fig. 4]), speaking also on behalf of her co-authors (also appearing in [Fig. 4]): “We were surprised and greatly honored to receive one of the 2022 Eberhard F. Mammen ‘Most Popular’ awards for the ‘General Category.’ The idea of our article entitled ‘Dosage of anticoagulants in obesity: recommendations based on a systematic review’ originated from questions regarding anticoagulant treatment of obese patients that came with increasing frequency in our center of thrombosis and hemostasis. We are grateful to know that our article was widely read by medical doctors, presumably treating obese patients in daily clinical practice; a clinical challenge that has been increasing during the last decade world-wide. And we strongly hope that our article was helpful to guide anticoagulant management of these patients.”
Fig. 4 From left: Anders Abildgaard, Sofie A. Madsen, Anne-Mette Hvas.
From Oliver Grottke ([Fig. 5]), speaking also on behalf of his co-authors (most of whom also appear in [Fig. 5]): “We are delighted to be bestowed a 2022 Eberhard F. Mammen ‘Most Popular’ article award for our article entitled ‘Fibrinogen Supplementation and Its Indications.’ This honor affirms our commitment to dissemination of new clinical developments and applications of point of care guided fibrinogen replacement strategies to restore hemostasis and minimize blood loss and transfusions. I would like to thank my wonderful co-authors for all their contributions to the field of perioperative blood management in various settings, including postpartum hemorrhage, cardiac surgery, trauma, liver disease, and pediatric patients. This wide input substantially improved the relevance of the paper to the journal's readership. Although we need further clinical studies to answer several important clinical questions, existing data do indicate that, in patients with ongoing bleeding related to acquired hypofibrinogenemia, fibrinogen concentrate has important advantages over frozen plasma and cryoprecipitate. Thank you again for the opportunity to share this paper with your readership and for the award. We are extremely honored.”
Fig. 5 From left: Oliver Grottke, Keyvan Karkouti, Fuat Saner, Thorsten Haas.
Also interesting is that several papers on the top 100 listing were co-authored by previous Young Investigator Award winners, for example the paper by Laridan et al,[10] which just missed out on a 2021 Most Popular award last year, being third on the list on that occasion, was again on the top list (ninth) on this occasion. Elodie Laridan was a 2017 Young Investigator Award winner,[59] and this paper represents the contribution submitted as part of the award. This also further helps to validate the Young Investigator Awards process itself.
Also, perhaps notable is that several of the papers listed on the most popular tables are original studies.[9]
[11]
[15]
[60] This is interesting given the current restrictive Publication Policy for original studies published in STH.[61] In brief, STH publishes a maximum of 10 to 12 original studies per year, and these also require additional oversight with external to STH Board peer review. Nonetheless, the fact that 1/11 original studies published in 2019 and that 2/8 original studies published in 2021 appeared in the top 100 seems to validate the Editorial Board's decision to continue to publish select unsolicited submissions of original studies. Of note, an original study also won one of the 2020 Most Popular awards.[60]
[62] Moreover, one original study[15] was submitted by a 2020 Young Investigator Awardee (Matthias Engelen)[63] as a condition of the award.
I would, as always, like to thank not only all of the authors listed in [Tables 2] and [5], but also all the other contributing authors who did not manage to make these listings, as well as all the many other guest editors of issues recently published in STH. I likewise look forward to seeing future listings—always a great pleasure and sometimes a surprise.
